A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—may help explain why people with inflammatory bowel disease (IBD) have a ...

The results of research headed by a team in the lab of Michael Sigal, MD, at the Max Delbrück Center and Charité—Universitätsmedizin Berlin, have shed new light on the role of the p53 tumor suppressor ...

Several specific genetic mutations have been associated with colorectal cancer (CRC) and dysplasia in patients with ulcerative colitis (UC). [1] Many of these genetic alterations are unique to ...

Risk of venous thromboembolism and cardiovascular events in ulcerative colitis (UC) patients on advanced therapies were lower with vedolizumab (Entyvio) compared with TNF inhibitors in a real-world ...